

Electronic supplementary material: Treatment of positive catheter tip culture without bloodstream infections in critically ill patients. A case cohort study from the OutcomeRéa network.

Results of the survey by experts

In the absence of high-quality evidence on the management of positive catheter-tip cultures, we conducted a survey to identify variables associated with antimicrobial treatment that should be included in the propensity score.

A questionnaire was sent to 75 attending experts (*i.e.*, intensivists, infectious diseases specialists, infection prevention and control specialists) from participating centers of the database or national experts from two countries (*i.e.*, France and Switzerland) on which factors influence the management of positive catheter tip cultures. We received 45 responses to 14 questions (eTable 1 and eTable 2).

Only 6 respondents (13%) stated that they would never treat a positive catheter tip culture without a concomitant positive blood culture. Severity of the patient, shock, occurrence of fever, decrease in temperature after catheter removal, presence of immunosuppression, presence of vascular and non-vascular prostheses, duration of catheter maintenance before removal, presence of exit signs of infection were all considered important in the therapeutic decision. Twelve out of 17 respondents mentioned that catheter venous thrombosis was also an important point for starting antimicrobial treatment. Therefore, we decided to include mostly of these risk factors for treatment in the same logistic regression model to determine the individual propensity to treat for each patient.

In which situation would you start an antimicrobial treatment?	Never N (%)	Rarely N (%)	Sometimes N (%)	Often N (%)	Always N (%)
1-A catheter tip colonization with a culture threshold $\geq 10^3$ CFU/ml, without positive blood culture except coagulase negative staphylococci	6 (13.3)	13 (28.9)	23 (51.1)	3 (6.7)	0
2-In case of concomitant fever > 38.5°C	1 (2.2)	13 (28.9)	15 (33.3)	12 (26.7)	4 (8.9)
3-According to the microorganism identified					
<i>Staphylococcus aureus</i>	3 (6.7)	9 (20)	9 (20)	15 (33.3)	9 (20)
<i>Pseudomonas aeruginosa</i>	3 (6.7)	14 (31.1)	8 (17.8)	14 (31.1)	6 (13.3)
<i>Candida albicans</i>	3 (6.7)	8 (17.8)	10 (22.2)	15 (33.3)	9 (20)
<i>Streptococcus</i> spp	8 (17.8)	10 (22.2)	21 (46.7)	3 (6.7)	3 (6.7)
<i>Enterococcus faecalis</i> or <i>faecium</i>	8 (17.8)	12 (26.7)	19 (42.2)	3 (6.7)	3 (6.7)
<i>Acinetobacter baumannii</i>	6 (13.3)	17 (37.8)	13 (28.9)	6 (13.3)	3 (6.7)
Anaerobic bacteria	12 (26.7)	11 (24.4)	20 (44.4)	1 (2.2)	1 (2.2)
<i>Staphylococcus lugdunensis</i>	5 (11.1)	8 (17.8)	19 (42.2)	9 (20)	4 (8.9)
4-In case of immunosuppression	2 (4.4)	16 (35.6)	11 (24.4)	14 (31.1)	2 (4.4)
5-In case of local signs	2 (4.4)	10(22,2)	4 (8.9)	20 (44.4)	9 (20)

eTable 1 Summary of the first part of the panel answers

Which of the following elements, in addition to those discussed above, do you consider to start an antimicrobial treatment?	Not at all relevant N (%)	Not relevant N (%)	No opinion N (%)	Relevant N (%)	Highly relevant N (%)	Mandatory N (%)
6-Duration of insertion of the catheter suspected at the time of removal	5 (11.1)	22 (48.9)	4 (8.9)	9 (20)	5 (11.1)	
7-Fever reduced by 0.5 degrees after catheter removal	2 (4.4)	9 (20)	3 (6.7)	18 (40)	11 (24.4)	2 (4.4)
8-A high SOFA score at catheter removal	5 (11.1)	11 (24.4)	5 (11.1)	17 (37.8)	6 (13.3)	1 (2.2)
9-Presence of septic shock at catheter removal	2 (4.4)	1 (2.2)	1 (2.2)	8 (17.8)	22 (48.9)	11 (24.4)
10- Presence of sepsis at catheter removal	2 (4.4)	3 (6.7)	4 (8.9)	19 (42.2)	12 (26.7)	5 (11.1)
12- Presence a non-vascular prosthesis	3 (6.7)	6 (13.3)	3 (6.7)	17 (37.8)	10 (22.2)	6 (13.3)
13- Presence of a vascular prosthesis	2 (4.4)	2 (4.4)	5 (11.1)	16 (35.6)	12 (26.7)	8 (17.8)

eTable2: Summary of the second part of panel answers

eTable 3: Microorganisms identified in positive intravascular catheter tip cultures.

Microorganism group	Total	With adequate treatment within 48h (n=279)	Without adequate treatment within 48h (n=222)
Non-fermenting Gram-negative, n (%)	123 (24.6)	60 (21.5)	63 (28.4)
<i>Candida</i> spp, n (%)	14 (2.8)	7 (2.5)	7 (3.2)
<i>S. aureus</i> , n (%)	59 (11.8)	44 (15.8)	15 (6.8)
Enterobacterales, n (%)	220 (43.9)	123 (44.1)	97 (43.7)
<i>Enterococcus</i> spp, n (%)	72 (14.4)	35 (12.5)	37 (16.7)
Other Gram-positive microorganisms, n (%)	13 (2.6)	10 (3.6)	3 (1.4)

Legend. We illustrated more than one microorganism per episode. Spp: species.

eTable 4: Logistic regression model used to develop the propensity score for adequate antimicrobial therapy within 48 hours.

Parameter	OR	CI 95%	p-value	
Sepsis			0.5967	
Without sepsis	1			
Sepsis	1.265	0.751	2.128	
Septic shock	1.458	0.657	3.238	
Temperature >38.5°C	2.075	1.194	3.608	0.0097
SOFA score at time of catheter tip colonization	0.973	0.906	1.046	0.4615
Number of days before catheter tip colonization	0.985	0.969	1.001	0.0594
Immunosuppression	2.583	1.413	4.725	0.0021
Thrombosis at time of catheter colonization	0.605	0.091	3.999	0.6016
Decrease in temperature of >0.5° after catheter removal	1.112	0.65	1.902	0.6988
<i>S. aureus</i>	2.69	1.375	5.261	0.0039
<i>P. aeruginosa</i>	0.959	0.574	1.601	0.8717
<i>Candida</i> spp	1.095	0.361	3.319	0.8721
<i>Streptococcus</i> spp	2.546	0.655	9.9	0.1774
<i>Enterococcus</i> spp	0.766	0.439	1.336	0.3469
<i>Acinetobacter</i> spp	0.676	0.232	1.97	0.4733

Legend. SOFA: Sequential Organ Failure Assessment. OR: Odds ratio. CI: Confidence interval. Spp: species. The AUC was 0.675. For our variables of interest, no missing values were observed. For SOFA and number of days before catheter tip colonization log-linearity was checked.

eTable 5: Microorganisms recovered in subsequent infections


Microorganisms	Matched population (n=30)		With adequate therapy within 48h (n=15)		Without adequate therapy within 48h (n=15)	
	Bloodstream infections (n=8)	Other (n=22)	Bloodstream infections (n=5)	Other (n=10)	Bloodstream infections (n=3)	Other (n=12)
<i>Staphylococcus aureus</i>	1	0	1	0	0	0
<i>Enterococcus faecalis</i>	0	1	0	1	0	0
<i>Enterococcus faecium</i>	0	2	0	2	0	0
<i>Proteus mirabilis</i>	0	4	0	2	0	2
<i>Serratia</i>	1	0	1	0	0	0
<i>Citrobacter freundii</i>	0	3	0	0	0	3
<i>Escherichia coli</i>	2	4	1	2	1	2
<i>Enterobacter cloacae</i>	1	3	0	0	1	3
<i>Klebsiella pneumoniae</i>	1	2	1	2	0	0
<i>Pseudomonas aeruginosa</i>	1	4	0	3	1	1
<i>Stenotrophomonas maltophilia</i>	0	1	0	0	0	1
<i>Corynebacterium JK.</i>	1	0	1	0	0	0
Polymicrobial	0	2	0	2	0	0

eTable 6: Subsequent infection and mortality risk for patients treated with and without adequate therapy within 48 hours after catheter removal.

	n/N adequate therapy within 48h	n/N without adequate therapy within 48h	sHR or HR	CI 95%	p-value
Subsequent infection risk at Day 30 with adequate antimicrobial therapy, n (%)					
Matched population	15/150	15/150	1.083	(0.622-1.887)	0.778
In patients with high-risk microorganisms	7/64	3/64	2.333	(0.833-6.536)	0.107
In patients with sepsis	11/83	12/83	0.833	(0.459-1.512)	0.549
Subsequent infection risk at Day 15 with adequate antimicrobial therapy, n (%)					
Matched population	15/150	14/150	1.182	(0.669-2.089)	0.566
In patients with high-risk microorganisms	7/64	3/64	2.333	(0.833-6.536)	0.107
In patients with sepsis	11/83	11/83	0.909	(0.496-1.667)	0.758
30-day mortality with adequate antimicrobial therapy, n (%)					
Matched population	33/150	29/150	0.889	(0.453-1.743)	0.732
In patients with high-risk microorganisms	17/64	14/64	1.222	(0.506-2.949)	0.655
In patients with sepsis	27/83	20/83	1.200	(0.605-2.381)	0.602
15-day mortality with adequate antimicrobial therapy, n (%)					
Matched population	25/150	20/150	1.000	(0.489-2.046)	1.000
In patients with high-risk microorganisms	13/64	9/64	1.250	(0.493-3.167)	0.638
In patients with sepsis	20/83	14/83	1.167	(0.540-2.522)	0.695


Legend. CI: Confidence Interval. HR: Hazard ratio. SHR: subdistribution hazard ratio.

eFigure 1: Standardized mean difference (SMD) before and after matching process of the main patient' and catheter' characteristics.



Legend: a SMD <0.1 after matching is considered to be optimal. Spp: species. SOFA: Sequential Organ Failure Assessment. ICU: intensive care unit.

eFigure 2: Distribution of propensity scores according to the adequacy of antimicrobial therapy within 48 hours, stratified by the quintile of propensity score.



Legend. This figure illustrated the distribution of propensity scores. We graphically observed a good overlap between patients with and without adequate treatment within 48 hours.

Supplementary analysis for patients with and without delayed antibiotic therapies

The impact of absence of treatment or delayed treatment (i.e., within 96 hours) was not assessed in our study. For this reason we performed a post-hoc analysis including controls without an adequate antibiotic therapy within 96h (n=119) and matched cases (n=119) with an adequate therapy within 48 hours. Using Cox proportional hazard models, the 30-day mortality risk was similar between patients non treated patients within 96h and treated within 48h (HR 0.86, 95% CI 0.40–1.85, p=0.70). Using subdistribution hazard models, the daily risk to develop subsequent infection up to Day-30 was similar between patients non-treated within 96h and treated within 48h (sHR 1.22, 95% CI 0.65–2.29, p=0.53). Moreover, we performed a sensitivity analysis including controls who received an adequate therapy between 48 and 96 hours (n=31) and matched cases with an adequate therapy within 48 hours. Using Cox proportional hazard models, the 30-day mortality risk was similar between patients treated between 48h and 96h and treated within 48h (HR 1.00, 95% CI 0.25–4.00, p=1.00). Using subdistribution hazard models, the daily risk to develop subsequent infection up to Day-30 was non-significantly reduced between patients treated between 48h and 96h and treated within 48h (sHR 0.33, 95% CI 0.09–1.18, p=0.09).

MEMBERS OF THE OUTCOMEREA STUDY GROUP

Scientific Committee: Jean-François Timsit (Medical and Infectious Diseases ICU, Bichat-Claude Bernard Hospital, Paris, France; UMR 1137 Inserm –Paris Diderot university IAME, F75018, Paris); Elie Azoulay (Medical ICU, Saint Louis Hospital, Paris, France); Maïté Garrouste-Orgeas (Paliative care, Institut franco Britanique, Paris, France); Jean-Ralph Zahar (Infection Control Unit, Angers Hospital, Angers, France); Bruno Mourvillier (Medical ICU, CHU Reims,France); Michael Darmon (Medical ICU, APHP Saint Louis hospital Paris, France); Niccolò Buetti (Geneva, Switzerland).

Biostatistical and Information System Expertise: Jean-Francois Timsit (Medical and Infectious Diseases ICU, Bichat-Claude Bernard Hospital, Paris, France; UMR 1137 Inserm –Paris Diderot university IAME, F75018, Paris); Corinne Alberti (Medical Computer Sciences and Biostatistics Department, Robert Debré Hospital, Paris, France); Stephane Ruckly (OUTCOMEREA organization and Inserm UMR 1137

IAME, F75018, Paris); Sébastien Bailly (Grenoble university hospital Inserm UMR 1137 IAME, F75018, Paris) and Aurélien Vannieuwenhuyze (Tourcoing, France).

Investigators of the OUTCOMEREA Database: Christophe Adrie (ICU, CH Melun, and Physiology, Cochin Hospital, Paris, France); Carole Agasse (medical ICU, university hospital Nantes, France); Bernard Allaouchiche (ICU, Hospices civils de Lyon, Lyon sud, Lyon, France); Olivier Andremont (ICU, Bichat Hospital, Paris, France); Pascal Andreu (CHU Dijon, Dijon, France); Laurent Argaud (Medical ICU, Hospices Civils de Lyon, Lyon, France); Elie Azoulay (Medical ICU, Saint Louis Hospital, Paris, France); Francois Barbier (medical-surgical ICU, Orleans, France), Jean-Pierre Bedos (ICU, Versailles Hospital, Versailles, France); Jérôme Bedel (ICU, Versailles Hospital, Versailles, France), Asael Berger (ICU, CH Haguenau, France) ; Julien Bohé (ICU, Hôpital Pierre Benite, Lyon France), Lila Bouadma (ICU, Bichat Hospital, Paris, France); Jeremy Bourenne (Réanimation des urgences, Timone-2; APHM, Marseille, France); Noel Brule (medical ICU, university hospital Nantes, France); Frank Chemouni (Grand Hôpital de l'Est Francilien Site Marne La vallée ; Polyvalent ICU, 77600 Jossigny Polyvalent ICU) ; Julien Carvelli (Réanimation des urgences, Timone-2; APHM, Marseille, France); Martin Cour Medial ICU, Edouard Heriot hospital, Lyon France), Michael Darmon (ICU, APHP St louis, Paris France); Julien Dessajan (ICU, Bichat Hospital, Paris, France), Claire Dupuis (ICU, G Montpied Hospital, Clermont-Ferrand, France), Etienne de Montmollin (ICU, Bichat Hospital, Paris, France), Marc Doman (ICU AP HP Bichat, paris France) ; Loa Dopeux (ICU, G Montpied Hospital, Clermont-Ferrand, France); Anne-Sylvie Dumenil (Antoine Béclère Hospital, Clamart, France); Claire Dupuis (Bichat hospital and UMR 1137 Inserm – Paris Diderot university IAME, F75018, Paris, France), Jean-Marc Forel (AP HM, Medical ICU, Hôpital Nord Marseille), Marc Gainnier (Réanimation des urgences, Timone-2; APHM, Marseille, France), Charlotte Garret (medical ICU, university hospital Nantes, France); Louis-Marie Galerneau (CHU A Michallon, Grenoble, France), Dany Goldgran-Tonedano (CH le Raincy-Montfermeil; France); Steven Grangé (ICU, CHU Rouen, France), Antoine Gros (ICU, Versailles Hospital, Versailles, France), Hédia Hamed (CH le Raincy-Montfermeil) ; Akim Haouache (Surgical ICU, H Mondor Hospital,

Creteil, France); Tarik Hissem (ICU, Eaubonne, France), Vivien Hong Tuan Ha (ICU, CH Meaux, France); Sébastien Jochmans (ICU, CH Melun); Jean-Baptiste Joffredo (ICU, G Montpied Hospital, Clermont-Ferrand, France); Hatem Kallel (ICU, Cayenne General Hospital, Cayenne, France); Guillaume Lacave (ICU, Versailles Hospital, Versailles, France), Virgine Laurent (ICU, Versailles Hospital, Versailles, France), Alexandre Lautrette (ICU, G Montpied Hospital, Clermont-Ferrand, France); Clément Le bihan (ICU, Bichat Hospital, Paris, France), Virgine Lemiale (Medical ICU, Saint Louis Hospital, Paris, France); David Luis (Médecine intensive et réanimation, CH Simone Veil, Beauvais, France), Guillaume Marcotte (Surgical ICU, Hospices Civils de Lyon, Lyon, France); Jordane Lebut (ICU, Bichat Hospital, Paris, France); Bruno Mourvillier (ICU, Bichat Hospital, Paris, France); Benoît Misset (ICU, Saint-Joseph Hospital, Paris, France); Bruno Mourvillier (ICU, Medical ICU, Reims France); Mathild Neuville (ICU, Foch Hospital, Paris, France); Laurent Nicolet (medical ICU, university hospital Nantes, France); Johanna Oziel (Medico-surgical ICU, hôpital Avicenne APHP, Bobigny, France), Laurent Papazian (Hopital Nord, Marseille, France), Juliette Patrier (ICU, Bichat Hospital, Paris, France), Benjamin Planquette (pulmonology ICU, George Pompidou hospital Hospital, Paris, France); Aguila Radjou (ICU, Bichat Hospital, Paris, France), Marie Simon (Medial ICU, Edouard Heriot hospital, Lyon France), Romain Sonnevile (ICU, Bichat Hospital, Paris, France), Jean Reignier (medical ICU, university hospital Nantes, France); Bertrand Souweine (ICU, G Montpied Hospital, Clermont-Ferrand, France); Carole Schwebel (ICU, A Michallon Hospital, Grenoble, France); Shidasp Siami (ICU, Eaubonne, France); Romain Sonnevile (ICU, Bichat Hospital, Paris, France); Michael thy (ICU, Bichat Hospital, Paris, France); Gilles Troché (ICU, Antoine Béclère Hospital, Clamart, France); Fabrice Thiollieres (ICU, Hospices civils de Lyon, Lyon sud, Lyon, France); Guillaume Thierry (ICU, St Etienne, France); Michael Thy (ICU, APHP, Bichat France); Guillaume Van Der Meersch (Medical Surgical ICU, university hospital Avicenne), Marion Venot (Medical ICU, Saint Louis Hospital, Paris, France); Florent Wallet (ICU, Hospices civils de Lyon, Lyon sud, Lyon, France); Sondes Yaacoubi (CH le Raincy-Montfermeil); Olivier Zambon (medical ICU, university hospital Nantes, France); Jonathan Zarka (reanimation polyvalente, centre hospitalier de marne la Vallee, France). Kévin grapin (ICU, G Montpied Hospital, Clermont-Ferrand,

France), Francois thouy (ICU, G Montpied Hospital, Clermont-Ferrand, France), Laure Calvet (ICU, G Montpied Hospital, Clermont-Ferrand, France), kevin Grapin (ICU, G Montpied Hospital, Clermont-Ferrand, France), guillaume laurichesse (ICU, G Montpied Hospital, Clermont-Ferrand, France), Martin COUR (Medical ICU, Hospices Civils de Lyon, Lyon, France), Neven STEVIC (Medical ICU, Hospices Civils de Lyon, Lyon, France).

Study Monitors: Mireille Adda, Vanessa Vindrieux, Marion Provent, Pauline Enguerrand, Vincent Gobert, Stéphane Guessens, Helene Merle, Nadira Kaddour, Boris Berthe, Samir Bekkhouche, Kaoultar Mellouk, Méline Lebrazic, Carole Ouisse, Diane Maugars, Christelle Aparicio, Igor Theodose, Manal Nouacer, Veronique Deiler, Fariza Nait Sidenas, Myriam Moussa, Atika Mouaci, Nassima Viguier.